Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).

@article{Holland2017LifitegrastFT,
  title={Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).},
  author={Edward J. Holland and Jodi I. Luchs and Paul M. Karpecki and Kelly K Nichols and Mitchell A. Jackson and Kenneth N. Sall and Joseph Tauber and Monica Roy and Aparna Raychaudhuri and Amir Shojaei},
  journal={Ophthalmology},
  year={2017},
  volume={124 1},
  pages={53-60}
}
PURPOSE Lifitegrast is a lymphocyte function-associated antigen-1 antagonist developed to reduce inflammation in dry eye disease (DED). We report the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of lifitegrast versus placebo in participants with DED. DESIGN Twelve-week, phase III, randomized, double-masked, multicenter, placebo-controlled study. PARTICIPANTS Adults aged ≥18 years with Schirmer tear test (without anesthesia) ≥1 and ≤10 mm, corneal… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…